Ladenburg Thalmann has recently reduced CNS Pharmaceuticals Inc (CNSP) stock to Neutral rating, as announced on December 28, 2020, according to Finviz. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
CNS Pharmaceuticals Inc (CNSP) Stock Trading Recap
On Monday, CNS Pharmaceuticals Inc (CNSP) stock saw a decline, ending the day at $0.13 which represents a decrease of $-0.01 or -7.14% from the prior close of $0.14. The stock opened at $0.14 and touched a low of $0.13 during the day, reaching a high of $0.14. The volume of shares traded was 1.33 million falling short of the average volume of 5.48 million.
CNSP Stock Performance and Moving Averages
In recent trading, CNS Pharmaceuticals Inc (CNSP) stock price has shown some volatility, fluctuating -6.79% over the last five trades and -11.22% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -99.27%, and it has plunged by -90.81% in the previous three months. Currently, CNSP is trading at -11.79%, -56.06%, and -99.12% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, CNSP, a Healthcare sector stock, is trading -99.91% below its 52-week high but remains 36.65% above its 52-week low. The Average True Range (ATR) (14 days) of 0.03 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
CNS Pharmaceuticals Inc’s Profitability and Valuation Ratios
CNS Pharmaceuticals Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -99.27%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, CNS Pharmaceuticals Inc’s market capitalization stands at $4.20 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.81% of CNS Pharmaceuticals Inc (CNSP)’s shares, while financial institutions hold 0.45%.
